Fulvestrant (Faslodex™) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases : combined results from two multicentre trials

Nom du journal : Eur J Cancer

Année : 2003

Volume : 39

Page de départ : 1228

Page de fin : 1233

Auteurs: Mauriac L, Pippen JE, Quaresma Albano J, Gertler SZ, Osborne CK, Markovits J,